Paper26626558
Future directions in the treatment of osteosarcoma.
Bishop MW and 2 others. Curr Opin Pediatr, 2016. Cited by 229 papers, by iCite.
Cite this record
ConductScience Library. Future directions in the treatment of osteosarcoma. Papers, record 26626558. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26626558
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bone Neoplasms | Major topic |
| Immunotherapy | Major topic |
| Molecular Targeted Therapy | Major topic |
| Osteosarcoma | Major topic |
| Biomarkers, Tumor | |
| Chemotherapy, Adjuvant | |
| Child | |
| Chromosome Aberrations | |
| Genetic Predisposition to Disease | |
| Humans | |
| Karyotype | |
| Prognosis |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA013330 | NCI NIH HHS | United States | P30CA013330 | PubMed and NIH | NIH RePORTER |
| U01 CA199221 | NCI NIH HHS | United States | U01CA199221 | PubMed and NIH | NIH RePORTER |
| UL1 TR001425 | NCATS NIH HHS | United States | UL1TR001425 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04890067 | Observational Study in Localized Osteosarcoma | Background |
Source ClinicalTrials.gov
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18235123 | Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18235123 | PubMed |
| 2 | 23520471 | Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. | PLoS One | 2013 | https://conductscience.org/library/papers/23520471 | PubMed |
| 3 | 25765070 | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. | Science | 2015 | https://conductscience.org/library/papers/25765070 | PubMed |
| 4 | 25611047 | A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation. | Pediatr Blood Cancer | 2015 | https://conductscience.org/library/papers/25611047 | PubMed |
| 5 | 21529352 | WEE1 inhibition sensitizes osteosarcoma to radiotherapy. | BMC Cancer | 2011 | https://conductscience.org/library/papers/21529352 | PubMed |
| 6 | 23339462 | MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. | Genome Med | 2013 | https://conductscience.org/library/papers/23339462 | PubMed |
| 7 | 25421877 | EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. | Ann Oncol | 2015 | https://conductscience.org/library/papers/25421877 | PubMed |
| 8 | 25512523 | Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. | Proc Natl Acad Sci U S A | 2014 | https://conductscience.org/library/papers/25512523 | PubMed |
| 9 | 25961939 | A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. | Nat Genet | 2015 | https://conductscience.org/library/papers/25961939 | PubMed |
| 10 | 25751499 | Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. | J Immunother | 2015 | https://conductscience.org/library/papers/25751499 | PubMed |
| 11 | 12743156 | Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12743156 | PubMed |
| 12 | 21527590 | A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. | Ann Oncol | 2012 | https://conductscience.org/library/papers/21527590 | PubMed |
| 13 | 24912408 | Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. | Pediatr Blood Cancer | 2014 | https://conductscience.org/library/papers/24912408 | PubMed |
| 14 | 26305408 | Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. | Pediatr Blood Cancer | 2016 | https://conductscience.org/library/papers/26305408 | PubMed |
| 15 | 25409260 | Genetic basis for clinical response to CTLA-4 blockade in melanoma. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25409260 | PubMed |
| 16 | 23434734 | The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23434734 | PubMed |
| 17 | 24166473 | Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. | Cancer | 2014 | https://conductscience.org/library/papers/24166473 | PubMed |
| 18 | 24866169 | Programmed cell death ligand 1 expression in osteosarcoma. | Cancer Immunol Res | 2014 | https://conductscience.org/library/papers/24866169 | PubMed |
| 19 | 23311495 | MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma. | Orphanet J Rare Dis | 2013 | https://conductscience.org/library/papers/23311495 | PubMed |
| 20 | 25642322 | Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma. | Clin Sarcoma Res | 2015 | https://conductscience.org/library/papers/25642322 | PubMed |
Cited by173
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 229 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42711706 | Phototherapy-responsive nanoplatform with hydrogel delivery potentiates immunotherapy and inhibits lung metastasis in osteosarcoma via synergistic glycolysis inhibition and vascular normalization. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42711706 | PubMed |
| 42403956 | FBXL5 depletion as a novel strategy against osteosarcoma: Evidence for MEK/ERK inhibition and enhanced therapeutic sensitivity. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42403956 | PubMed |
| 42272640 | Heterogeneity-based stratification identifies CKMT2 as a prognostic marker in osteosarcoma. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42272640 | PubMed |
| 41827906 | PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells. | Cells | 2026 | https://conductscience.org/library/papers/41827906 | PubMed |
| 41118012 | Pan-cancer analysis of role of LOXL4 and experiment validation in osteosarcoma. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41118012 | PubMed |
| 41078460 | CXCL10-induced chemotaxis of ex vivo-expanded natural killer cells combined with NKTR-255 enhances anti-tumor efficacy in osteosarcoma. | Mol Ther Oncol | 2025 | https://conductscience.org/library/papers/41078460 | PubMed |
| 40599602 | The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma. | Oncol Rev | 2025 | https://conductscience.org/library/papers/40599602 | PubMed |
| 40534850 | Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights. | Front Immunol | 2025 | https://conductscience.org/library/papers/40534850 | PubMed |
| 40512277 | Gambogic acid suppresses osteosarcoma progression through upregulation of FOXO3a. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40512277 | PubMed |
| 39995821 | Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives. | Front Immunol | 2024 | https://conductscience.org/library/papers/39995821 | PubMed |
| 39962461 | Integrated analysis of single-cell and bulk transcriptomics reveals cellular subtypes and molecular features associated with osteosarcoma prognosis. | BMC Cancer | 2025 | https://conductscience.org/library/papers/39962461 | PubMed |
| 39825088 | Integrins identified as potential prognostic markers in osteosarcoma through multi-omics and multi-dataset analysis. | NPJ Precis Oncol | 2025 | https://conductscience.org/library/papers/39825088 | PubMed |
| 39781890 | Inhibition of DKK-1 by WAY262611 Inhibits Osteosarcoma Metastasis. | Mol Cancer Ther | 2025 | https://conductscience.org/library/papers/39781890 | PubMed |
| 39727177 | LncRNA-associated ceRNA Network Revealing the Potential Regulatory Roles of Ferroptosis and Immune Infiltration in Osteosarcoma as well as Construction of the Prognostic Model. | Curr Med Chem | 2025 | https://conductscience.org/library/papers/39727177 | PubMed |
| 39590531 | Calcium Phosphate Loaded with Curcumin Prodrug and Selenium Is Bifunctional in Osteosarcoma Treatments. | J Funct Biomater | 2024 | https://conductscience.org/library/papers/39590531 | PubMed |
| 39015175 | LncRNAs as potential prognosis/diagnosis markers and factors driving drug resistance of osteosarcoma, a review. | Front Endocrinol (Lausanne) | 2024 | https://conductscience.org/library/papers/39015175 | PubMed |
| 38980440 | Investigation of prognostic values of immune infiltration and LGMN expression in the microenvironment of osteosarcoma. | Discov Oncol | 2024 | https://conductscience.org/library/papers/38980440 | PubMed |
| 38910902 | Hsa_circ_0064636 regulates voltage dependent anion channel 1/ubiquitination factor E4A through miR‑326/miR‑503‑5 in osteosarcoma. | Oncol Lett | 2024 | https://conductscience.org/library/papers/38910902 | PubMed |
| 38847977 | Neoadjuvant chemotherapy-induced hemoglobin decline as a prognostic factor in osteosarcoma around the knee joint: a single-center retrospective analysis of 242 patients. | Support Care Cancer | 2024 | https://conductscience.org/library/papers/38847977 | PubMed |
| 38769124 | Targeting the mitochondrial protein YME1L to inhibit osteosarcoma cell growth in vitro and in vivo. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/38769124 | PubMed |
Genes41
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26626558
GET https://conductscience.org/api/papers/v1/26626558/references?page=2